Circulating tumor cells (CTCs) that play a pivotal role in establishing metastases serve as biomarkers for diagnosis, treatment and prognosis of cancer. Death in more than 90% of cancer patients is found to be due to metastasis.\[[@ref1]\] Cancer cells are said to be detected in circulation even before the presentation of clinical symptoms.\[[@ref2]\] CTCs were reported to be present about 140 years ago.\[[@ref3]\]

CellSearch system (Veridex, Raritan, NJ, USA) was introduced in 2004. It is the only device cleared by Food and Drug Administration (FDA) for selecting and enumerating CTCs.\[[@ref4]\]

In patients with oral squamous cell carcinoma (OSCC), CTCs are regarded as prognostic markers for the disease -- free survival.\[[@ref5]\] In the peripheral blood, CTCs are extremely rare events, estimated to be around one cell among a hundred million or billion of circulating blood cells.\[[@ref6]\] Thus, an enrichment step is mandatory for efficient detection of these cells.

Development of Metastasis via Circulating Tumour Cells {#sec1-1}
======================================================

Epithelial-to-mesenchymal transition occurs when the tumor cells and clusters that are shed from the primary tumor intravasate into circulation. Apoptosis and necrosis kills a majority of CTCs, releasing debris, fragments of cells and intracellular elements (circulating tumor material and ctDNA). Circulating tumor microemboli (CTM) that are clusters of tumor cells, as a result of the collision may release the tumor cells. The CTCs then extravasate, leading to metastasis \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref7]\]

![Development of metastases via circulating tumor cells](JPBS-7-173-g001){#F1}

Circulating Tumor Cells Assays {#sec1-2}
==============================

Involves an initial enrichment step, where tumor cells are isolated following depletion of blood cellsThe tumor cells are stained or oncogene probed: The CTCs are labeled by antibodies or aptamers or probed by DNA primersTumor cell detection via cytometry, microscopy, conductometry, fiber-optics, reverse transcription- polymerase chain reaction (RT-PCR), fluorescence *in situ* hybridization and comparative genomic hybridization.

The enrichment methods depend on physical characteristics like size, density or dielectrophoretic mobility that exemplifies CTCs or by the expression of certain surface molecules that are captured by magnetic bead-coated antibodies. Gradient centrifugation is commonly done using ficoll-hypaque that uses density of different cell types. A substantial loss of cell material is however said to occur during enrichment.\[[@ref8]\] Monoclonal antibodies are available against different epithelial proteins, namely cytoskeleton keratins, surface adhesion molecules or growth factor receptors.

One of the most advanced methods for detecting and enumerating CTCs from peripheral blood is by the CellSearch system (Veridex, Raritan, NJ, United States) that enriches and immunostains CTCs. It is the first FDA-cleared device for CTC detection in solid tumors and for metastasized prostate, colon, and breast cancers.\[[@ref9][@ref10][@ref11][@ref12][@ref13]\] Gröbe *et al*. detected CTCs in a small number of OSCC patients.\[[@ref5]\] The EpCAM positive tumor cells are separated by immunomagnetic bead separation and are immunofluorescent stained with anti-keratin antibodies. The leukocytes are excluded using anti-CD45-antibody. Under fluorescent microscope, nucleated cells with a diameter of 4 μm, keratin positive and CD45 negative are accepted as tumor cells.\[[@ref14]\]

Other recently developed EpCAM-based tools include:

Microfluid-based CTC-chips\[[@ref15]\]Surface enhanced Raman spectroscopy with epidermal growth factor receptors as targeting ligand\[[@ref16]\]Detection of CTCs after the leukapheresis.\[[@ref17]\]

*In Vivo* Detection of Circulating Tumour Cells {#sec1-3}
===============================================

GILUPI cell collector device consisting of a wire coated with anti-EpCAM antibodies that collects CTCs when inserted into a vein for 30 min. Presence of CTCs and exclusion of leukocytes are confirmed with anti-keratin and ant-CD45 antibodies.\[[@ref18]\]

Epithelial Immunospots {#sec1-4}
======================

Involves detection of viable CTCs after a 48 h culture, where leukocytes are depleted by negative selection using CD45.\[[@ref19]\]

Molecular Technologies {#sec1-5}
======================

They involve PCR amplification based on either DNA or complementary DNA (messenger RNA). RT-PCR approaches use epithelium-specific targets, like keratin 19 encoding targets.\[[@ref20]\]

Recent Trends in Circulating Tumour Cells Research {#sec1-6}
==================================================

Detecting circulating tumor microemboli {#sec2-1}
---------------------------------------

A collective migration of tumor cells leads to the formation of CTM.\[[@ref21]\] These collective tumor cells intravasate through leaky blood vessel.\[[@ref22]\] CTMs exhibit a highly variable morphology: As clusters, circles or strands.\[[@ref23]\]

The likely cause of CTM formation is increased adhesiveness of circulating tumor cells.\[[@ref24]\]

Studies indicate CTM presence indicates higher metastatic potential.\[[@ref25]\] The suggested explanations are as follows:

CTMs are easily caught in narrow vessels than CTCs\[[@ref26]\]CTMs provide a favorable environment for survival of tumor cells\[[@ref24]\]EGF and VEGF stimulate proliferation and inhibit apoptosis.\[[@ref27]\]

Circulating tumor microemboli detection is done using flow cytometry\[[@ref28]\] or by cell search.

Circulating tumor cells detection based on telomerase activity {#sec2-2}
--------------------------------------------------------------

As telomerase activity inactivated in cancer\[[@ref29]\] and since tumor cells lose epithelial markers during metastasis, assessing telomerase activity would provide valuable information on CTCs. Since the whole blood sample has to be lysed to measure enzyme activity, CTCs get destroyed, which is a downside for the method.

Circulating tumor cells detection by aptamer technology {#sec2-3}
-------------------------------------------------------

Aptamers are single-stranded DNA or RNA molecules.\[[@ref30]\] Systemic evaluation of ligands by exponential enrichment automates aptamer production.\[[@ref31]\]

Conclusion {#sec1-7}
==========

With the advent of new technologies to detect CTCs current staging methods of cancer have been refined. Additional treatment options can now be made available for patients suffering from OSCC as collecting samples from peripheral blood is invasive. Tumor cells that undergo an epithelial-to-mesenchymal transition show downregulation of epithelial features. Hence, molecular analysis of CTCs is required. Advances have been made with aptamers and microdevices that minimize technical constraints. CTCs have to be evaluated by proteomics and genomics too.
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